A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

This is a first-in-human Phase 1 study testing a new oral drug called AO-252 in people with advanced solid tumors. The drug is designed to target a protein called TACC3, which plays a role in cancer cell growth. It also accepts patients whose cancer has spread to the brain. **You may be eligible if...** - You are 18 or older - You have an advanced solid tumor (most types, not melanoma) that has a TP53 gene mutation or loss, and your cancer has stopped responding to at least one prior treatment - You have castration-resistant prostate cancer (mCRPC) that has progressed after hormone therapy and/or chemotherapy - Your cancer may or may not have spread to the brain - You have adequate blood counts, liver, kidney, and heart function - Your overall health is good (ECOG performance status 0–1) - You have a life expectancy of at least 3 months **You may NOT be eligible if...** - Your brain metastases are causing symptoms that need immediate treatment - You have had another cancer in the last 3 years (other than treated skin cancer) - You have uncontrolled fluid buildup around the lungs or abdomen - You cannot swallow pills or have serious gut problems that affect absorption - You are pregnant or breastfeeding - You have active HIV, hepatitis B, or hepatitis C - You have significant heart rhythm problems - You took strong CYP3A4-affecting drugs within the last 14 days Talk to your doctor to see if this trial is right for you.